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A bs tr ac t
Background
We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leuco-
vorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought as-
sociations between the mutation status of the KRAS gene in tumors and clinical re-
sponse to cetuximab.
Methods
We randomly assigned patients with epidermal growth factor receptor–positive colo-
rectal cancer with unresectable metastases to receive FOLFIRI either alone or in combi-
nation with cetuximab. The primary end point was progression-free survival.
Results
A total of 599 patients received cetuximab plus FOLFIRI, and 599 received FOLFIRI 
alone. The hazard ratio for progression-free survival in the cetuximab–FOLFIRI 
group as compared with the FOLFIRI group was 0.85 (95% confidence interval [CI], 
0.72 to 0.99; P = 0.048). There was no significant difference in the overall survival 
between the two treatment groups (hazard ratio, 0.93; 95% CI, 0.81 to 1.07; P = 0.31). 
There was a significant interaction between treatment group and KRAS mutation status 
for tumor response (P = 0.03) but not for progression-free survival (P = 0.07) or over-
all survival (P = 0.44). The hazard ratio for progression-free survival among patients 
with wild-type–KRAS tumors was 0.68 (95% CI, 0.50 to 0.94), in favor of the cetux-
imab–FOLFIRI group. The following grade 3 or 4 adverse events were more frequent 
with cetuximab plus FOLFIRI than with FOLFIRI alone: skin reactions (which were 
grade 3 only) (in 19.7% vs. 0.2% of patients, P<0.001), infusion-related reactions (in 
2.5% vs. 0%, P<0.001), and diarrhea (in 15.7% vs. 10.5%, P = 0.008).
Conclusions
First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, 
reduced the risk of progression of metastatic colorectal cancer. The benefit of cetux-
imab was limited to patients with KRAS wild-type tumors. (ClinicalTrials.gov num-
ber, NCT00154102.)
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Colorectal cancer is the third most common cancer worldwide.1 Approximately 25% of patients with colorectal cancer pre-
sent with overt metastatic disease, and metastatic 
disease develops in 40 to 50% of newly diag-
nosed patients. Standard first-line treatments in-
clude fluo rouracil with leucovorin and irinotecan2,3 
or oxaliplatin,4 alone or combined with bevaci-
zumab.5
The immunoglobulin G1 monoclonal antibody 
against the epidermal growth factor receptor 
(EGFR), cetuximab (Erbitux), is effective in com-
bination with irinotecan in patients with meta-
static colorectal cancer or as a single agent in pa-
tients with metastatic colorectal cancer that 
progresses even when irinotecan is used.6,7 Phase 
1 and 2 studies have shown cetuximab to have 
activity when added to irinotecan-based thera-
py8,9 or oxaliplatin-based therapy10-12 as first-line 
treatment.
There are no biomarkers that reliably predict 
responses to cetuximab, but the examination of 
outcomes based on the presence of mutations of 
the KRAS gene shows promise. KRAS encodes a 
small G protein that links ligand-dependent re-
ceptor activation to intracellular pathways of the 
EGFR signaling cascade. Mutation at key sites 
within the gene, commonly at codons 12 and 13, 
causes constitutive activation of KRAS-associated 
signaling. Growing evidence indicates that tumor 
KRAS mutation is associated with the inefficacy 
of cetuximab13-17 and the monoclonal anti-EGFR 
immunoglobulin G2 antibody panitumumab.18,19
In our multicenter phase 3 trial, Cetuximab 
Combined with Irinotecan in First-Line Therapy 
for Metastatic Colorectal Cancer (CRYSTAL), we 
investigated the efficacy and safety of irinotecan 
in combination with a simplified regimen of f luo-
rouracil and leucovorin (FOLFIRI) plus cetuxi-
mab20 in the initial treatment of metastatic colo-
rectal cancer. We also conducted a retrospective 
subgroup analysis to investigate the influence of 
the tumor KRAS mutation status on outcome.
Me thods
Patients
Inclusion criteria were an age of 18 years or older, 
histologically confirmed adenocarcinoma of the 
colon or rectum, first occurrence of metastatic 
disease that could not be resected for curative pur-
poses, immunohistochemical evidence of tumor 
EGFR expression, Eastern Cooperative Oncology 
Group (ECOG) performance status score of 2 or 
less, and adequate hematologic, hepatic, and re-
nal function. Exclusion criteria were previous ex-
posure to an anti-EGFR therapy or irinotecan-based 
chemotherapy, previous chemotherapy for meta-
static colorectal cancer, adjuvant treatment that 
was terminated 6 months or less before the start 
of treatment in our trial, and the use of radiothera-
py, surgery (excluding previous diagnostic biopsy), 
or any investigational drug in the 30-day period 
before the start of treatment in our trial.
The protocol was approved by independent eth-
ics committees and the governmental authorities 
in each country, as required. The trial was carried 
out in accordance with the Declaration of Helsinki 
(October 1996). All patients provided written and 
oral informed consent.
Study Design
This trial was a randomized, open-label, multi-
center study comparing 14-day cycles of cetuximab 
plus FOLFIRI and FOLFIRI alone. We randomly 
assigned patients (in a 1:1 ratio) to one of the two 
treatment groups using a stratified permuted-block 
procedure, with ECOG performance status (0 or 
1 vs. 2) and region (sites in Western Europe vs. 
Eastern Europe vs. outside Europe) as stratifica-
tion factors.
The primary end point was progression-free 
survival time, defined as the time from random-
ization to disease progression or death from any 
cause within 60 days after the last tumor assess-
ment or after randomization. Secondary end points 
included the overall survival time, the rate of 
best overall response (the proportion of patients 
with a confirmed complete response or partial re-
sponse, defined as a response persisting for at 
least 28 days), and safety end points (including the 
incidence and type of adverse events, laboratory 
variables, and vital signs).
The number of patients undergoing surgery 
with a curative intent (any resection of metasta-
sis with a goal of cure or complete resection of all 
lesions to R0) was prospectively analyzed. A ret-
rospective subgroup analysis was used to inves-
tigate associations between the progression-free 
survival time, overall survival time, or response 
rate and the KRAS mutation status of tumors. An 
independent review committee (consisting of radi-
ologists and oncologists) performed a preplanned, 
blinded, retrospective review (based on modified 
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World Health Organization criteria) of radiologic 
assessments and clinical data to determine the 
day of progression and the best overall response.
The study was designed by Merck (Darmstadt) 
together with the primary academic investigator. 
Data were collected by principal investigators at 
each center, and statistical analyses were con-
ducted by a contract research organization (Quin-
tiles), supervised by Merck (Darmstadt). The pri-
mary academic investigator had access to all the 
data and vouches for the completeness and accu-
racy of the reported data and the analyses.
Treatment
On day 1 of each 14-day period during the study, 
patients in the FOLFIRI group received a 30- to 
90-minute infusion of irinotecan at a dose of 180 
mg per square meter of body-surface area; an in-
fusion, for 120 minutes, of racemic leucovorin or 
l-leucovorin at a dose of 400 or 200 mg, respec-
tively, per square meter of body-surface area; fluo-
rouracil in a bolus of 400 mg per square meter of 
body-surface area and then continuous infusion for 
46 hours of 2400 mg per square meter of body-
surface area.
During the study, patients in the cetuximab–
FOLFIRI group received cetuximab in an initial 
120-minute infusion on day 1 of 400 mg per 
square meter of body-surface area, followed by 60-
minute infusions of cetuximab at a dose of 250 mg 
per square meter of body-surface area, once week-
ly (Fig. 1 in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org). 
FOLFIRI was given after the cetuximab infusion 
on day 1 of each period.
Treatment was continued until disease progres-
sion, unacceptable toxic effects, or withdrawal of 
consent occurred. In the event of predefined toxic 
effects related to chemotherapy or cetuximab, 
protocol-specified treatment modifications were 
permitted.
Assessments
Computed tomography or magnetic resonance im-
aging was performed every 8 weeks until disease 
progression was observed to have occurred. Fol-
low-up evaluations were performed every 3 months. 
Adverse events (the severity of which were assessed 
according to the National Cancer Institute Com-
mon Toxicity Criteria, version 2.0) and concomi-
tant medication use were recorded continuously.
KRAS Mutation Status
DNA was extracted from formaldehyde-fixed, 
paraffin-embedded tumor-biopsy specimens and 
screened for KRAS mutations in codons 12 and 
13 with the use of a polymerase-chain-reaction 
(PCR) clamping and melting curve method21 (im-
plemented by means of a LightMix k-ras Gly12 as-
say, TIB MOLBIOL). PCR amplification of the wild-
type KRAS sequence was suppressed in this process 
by the incorporation in the reaction mix of a 
locked nucleic-acid oligomer22 spanning codons 
12 and 13 of the KRAS gene (see the Methods 
section in the Supplementary Appendix).
Statistical Analysis
We aimed to enroll enough patients to yield the 
occurrence of 633 progression events, which would 
give a statistical power of 80% to reject the null 
hypothesis of no significant difference in the pro-
gression-free survival time between the two treat-
ment groups, assuming a hazard ratio of 0.8 and 
a significance level of a two-sided log-rank test 
fixed at 5%. All statistical-analysis methods were 
prespecified. All reported P values are two-sided 
and were not adjusted for multiple testing.
Analysis of the progression-free survival time 
was based on Kaplan–Meier curves (product-limit 
estimates)23 and performed on all patients who 
received at least one dose of a study drug. Results 
between the two treatment groups were compared 
with the use of a log-rank test24 after stratifica-
tion according to the ECOG performance status 
and region. Secondary efficacy analyses were sup-
portive, exploratory, and nonconfirmatory. The 
rates of best overall response and surgery with 
curative intent were compared between the two 
treatment groups with the use of a Cochran–
Mantel–Haenszel test,25 stratified according to 
the randomization strata. The efficacy-analysis 
methods were repeated for the subgroup with 
samples that could be evaluated for KRAS muta-
tion status (the KRAS population). The heteroge-
neity of treatment effects between the subgroups 
with wild-type and mutant KRAS was explored 
retrospectively with the use of a statistical test for 
interaction applied through a Cox model for pro-
gression-free survival time and overall survival 
time and a logistic-regression model for overall 
response rate. Hazard and odds ratios are ex-
pressed for cetuximab plus FOLFIRI as compared 
with FOLFIRI alone.
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Safety analyses were carried out with the use 
of data from all patients receiving at least one dose 
of any study drug. Adverse events were catego-
rized according to the Medical Dictionary for Regu-
latory Activities (version 10.0) system organ classes 
and preferred terms, as well as predefined special 
adverse event categories in which the preferred 
terms are pooled.
R esult s
Patients
From July 2004 through November 2005, 2020 
patients were screened at 189 of the 201 centers, 
and 1217 underwent randomization, of which 1198 
were subsequently treated (599 in each of the two 
groups) at 184 centers (Fig. 2 in the Supplemen-
tary Appendix). Four patients were treated but did 
not undergo randomization; therefore, the safety 
population comprised 1202 patients (600 receiv-
ing cetuximab plus FOLFIRI and 602 receiving 
FOLFIRI alone).
In the safety population, the cetuximab–
FOLFIRI group had a median duration of 25.0 
weeks (interquartile range, 12.9 to 40.4) of cetux-
imab treatment, 26.0 weeks (interquartile range, 
14.0 to 40.3) of irinotecan treatment, and 26.0 
weeks (interquartile range, 13.8 to 40.4) of fluo-
rouracil treatment. The FOLFIRI group had a me-
dian duration of 25.7 weeks (interquartile range, 
15.1 to 35.9) of irinotecan treatment and 25.7 
weeks (interquartile range, 14.9 to 36.0) of fluo-
rouracil treatment. The median duration of follow-
up was 29.9 months (95% confidence interval [CI], 
29.1 to 30.5) with cetuximab plus FOLFIRI and 
29.4 months (95% CI, 28.8 to 30.4) with FOLFIRI 
alone. Seven patients were lost to follow-up — two 
in the cetuximab–FOLFIRI group and five in the 
FOLFIRI group. In the primary analysis popula-
tion, post-study chemotherapy with or without 
EGFR antibody therapy was administered to 63.9% 
and 6.2% of patients, respectively, receiving cetux-
imab plus FOLFIRI and 68.8% and 25.4%, respec-
tively, of those receiving FOLFIRI. The findings 
were similar for the KRAS population.
The study groups were well balanced in terms 
of baseline characteristics with regard to the pa-
tients, disease, and treatment (Table 1). Altogether, 
60.5% of the study population was male, 96.5% 
had an ECOG performance status of 0 or 1, and 
the colon was the primary tumor site in 60.2%.
Efficacy
Progression events occurred in 298 patients re-
ceiving cetuximab plus FOLFIRI and 322 receiv-
ing FOLFIRI alone; cetuximab–FOLFIRI treatment 
reduced the risk of progression by 15% as com-
pared with FOLFIRI alone (adjusted hazard ratio 
for cetuximab–FOLFIRI, 0.85; 95% CI, 0.72 to 
0.99; P = 0.048) (Fig. 1A and Table 2). The median 
progression-free survival times were 8.9 months 
with cetuximab plus FOLFIRI and 8.0 months with 
FOLFIRI alone. As of the cutoff date for collec-
tion of survival data of December 31, 2007, there 
were 412 deaths in the cetuximab–FOLFIRI group 
and 416 in the FOLFIRI group. The adjusted haz-
ard ratio for death with cetuximab plus FOLFIRI 
was 0.93 (95% CI, 0.81 to 1.07; P = 0.31) (Fig. 1B). 
Median overall survival times were 19.9 months 
in the cetuximab–FOLFIRI group and 18.6 months 
in the FOLFIRI group (Table 2). Confirmed com-
plete or partial tumor responses occurred in 281 
patients (46.9%) receiving cetuximab plus FOLFIRI 
and in 232 patients (38.7%) receiving FOLFIRI 
alone. The adjusted odds ratio for a tumor response 
with cetuximab–FOLFIRI treatment, as compared 
with FOLFIRI alone, was 1.40 (95% CI, 1.12 to 1.77; 
P = 0.004) (Table 2). The rate of surgery for metas-
tases was higher in the cetuximab–FOLFIRI group 
than in the FOLFIRI group (7.0% vs. 3.7%), as was 
the rate of R0 resection with curative intent before 
disease progression (4.8% vs. 1.7%; odds ratio for 
cetuximab–FOLFIRI, 3.02; 95% CI, 1.45 to 6.27; 
P = 0.002).
Subgroup Analysis According to KRAS 
Mutation Status
Tumor samples obtained at baseline from 540 pa-
tients were suitable for the analysis of KRAS mu-
tation status; samples from the remaining patients 
were either of insufficient size or not available. 
Tumors of 348 patients (64.4%) had wild-type KRAS 
and those of 192 patients (35.6%) had mutated 
KRAS. More patients in the FOLFIRI group than 
in the cetuximab–FOLFIRI group had wild-type–
KRAS tumors (66.9% vs. 62.1%). The hazard ra-
tios for progression were similar in the primary 
analy sis population (0.85) and the KRAS popula-
tion (0.82).
The association between KRAS mutation sta-
tus and treatment, with regard to progression-free 
survival, was not significant (P = 0.07), nor was 
there a significant treatment interaction for over-
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all survival (P = 0.44). There was, however, a sig-
nificant interaction of mutation status with tumor 
response (P = 0.03).
Hazard ratios for progression-free survival 
among patients receiving cetuximab plus FOLFIRI, 
as compared with FOLFIRI alone, who had tumors 
with wild-type KRAS and who had tumors with 
mutant KRAS were 0.68 (P = 0.02) and 1.07 (P = 0.75), 
respectively (Fig. 1C and 2A). Median progression-
free survival times with cetuximab–FOLFIRI and 
FOLFIRI were 9.9 months and 8.7 months, respec-
tively, in the wild-type–KRAS population and 7.6 
and 8.1 months, respectively, in the mutant-KRAS 
population. Hazard ratios for overall survival in 
the wild-type–KRAS and mutant-KRAS populations 
were 0.84 and 1.03, respectively (Fig. 1D and 2A). 
Table 1. Baseline Characteristics of the Study Patients in the Primary Analysis Population and the KRAS Population, According to  
Treatment Group.*
Variable
Primary Analysis 
Population KRAS Population Wild-Type KRAS Mutant KRAS
Cetuximab 
plus FOLFIRI 
(N = 599)
FOLFIRI 
Alone 
(N = 599)
Cetuximab 
plus FOLFIRI 
(N = 277)
FOLFIRI 
Alone 
(N = 263)
Cetuximab 
plus FOLFIRI 
(N = 172)
FOLFIRI 
Alone 
(N = 176)
Cetuximab 
plus FOLFIRI 
(N = 105)
FOLFIRI 
Alone 
(N = 87)
Male sex (%) 61.6 59.4 62.1 53.2 61.0 54.5 63.8 50.6
Age (yr)
Median 61 61 61 62 61 60.5 62 63
Range 22–82 19–84 22–79 22–79 24–79 22–79 22–79 32–79
Region (%)
Eastern Europe 33.9 33.6 50.2 51.7 48.8 48.9 52.4 57.5
Western Europe 43.7 44.6 41.9 43.3 41.3 46.0 42.9 37.9
Outside Europe 22.4 21.9 7.9 4.9 9.9 5.1 4.8 4.6
ECOG performance status (%)†
0 55.1 53.1 55.2 54.8 57.6 59.1 51.4 46.0
1 41.1 43.4 40.8 42.6 38.4 36.9 44.8 54.0
2 3.5 3.5 4.0 2.7 4.1 4.0 3.8 0.0
Laboratory values (%)
Lactate dehydrogenase >ULN 44.6 44.7 46.9 44.5 46.5 41.5 47.6 50.6
Alkaline phosphatase ≥300 U/liter 11.9 13.3 10.1 9.9 8.1 9.7 13.3 10.3
Leukocyte count >10,000/mm3 19.9 15.7 16.6 20.2 16.3 16.5 17.1 27.6
Previous therapy (%)
Adjuvant chemotherapy 18.9 17.4 16.2 14.8 19.2 16.5 11.4 11.5
Radiotherapy pretreatment 10.5 11.7 12.6 12.9 16.9 13.6 5.7 11.5
Site of primary tumor (%)
Colon 59.8 60.4 58.1 59.3 55.2 58.5 62.9 60.9
Rectum 38.1 37.6 40.4 39.9 44.2 40.9 34.3 37.9
Colon or rectum 2.0 1.8 1.1 0.8 0.6 0.6 1.9 1.1
Missing data 0.2 0.2 0.4 0.0 0.0 0.0 1.0 0.0
Metastases (%)
At one or two sites 83.5 86.1 84.8 84.4 86.0 84.7 82.9 83.9
Confined to liver 20.4 22.4 18.8 21.3 19.8 18.2 17.1 27.6
* FOLFIRI denotes fluorouracil, irinotecan, and leucovorin, and ULN the upper limit of the normal range.
† The Eastern Cooperative Oncology Group (ECOG) performance status score can range from 0 to 2, with higher scores indicating greater im-
pairment.
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Median overall survival times in the cetuximab–
FOLFIRI group and the FOLFIRI group were 24.9 
months and 21.0 months, respectively, in the wild-
type–KRAS population and 17.5 and 17.7 months, 
respectively, in the mutant-KRAS population. 
Among patients with wild-type–KRAS tumors, the 
response rate in the cetuximab–FOLFIRI group 
was 59.3% and in the FOLFIRI group 43.2% (odds 
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Figure 1. Kaplan–Meier Estimates of Progression-free and Overall Survival in the Primary Analysis Population and the Wild-Type–KRAS 
Population, According to Treatment Group.
Panel A shows progression-free survival among the 1198 patients in the primary analysis population. The hazard ratio for the cetuximab–
FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% CI, 0.72 to 0.99; P = 0.048 by a stratified log-rank test). Median progres-
sion-free survival time in the cetuximab–FOLFIRI group was 8.9 months (95% CI, 8.0 to 9.5), as compared with 8.0 months (95% CI, 7.6 to 
9.0) in the FOLFIRI group. Panel B shows overall survival among the 1198 patients in the primary analysis population. The hazard ratio for 
death in the cetuximab–FOLFIRI group as compared with the FOLFIRI group was 0.93 (95% CI, 0.81 to 1.07; P = 0.31 by a stratified log-rank 
test). The median overall survival in the cetuximab–FOLFIRI group was 19.9 months (95% CI, 18.5 to 21.3), as compared with 18.6 months 
(95% CI, 16.6 to 19.8) in the FOLFIRI group. Panel C shows progression-free survival among the 348 patients with wild-type–KRAS tumors. 
The hazard ratio for progression in the cetuximab–FOLFIRI group as compared with the FOLFIRI group was 0.68 (95% CI, 0.50 to 0.94; 
P = 0.02). The median progression-free survival in the cetuximab–FOLFIRI group was 9.9 months (95% CI, 8.7 to 14.6), as compared with 
8.7 months (95% CI, 7.4 to 9.9) in the FOLFIRI group. Panel D shows overall survival among the 348 patients with wild-type–KRAS tumors. 
The hazard ratio for death in the cetuximab–FOLFIRI group as compared with the FOLFIRI group was 0.84 (95% CI, 0.64 to 1.11). The me-
dian overall survival in the cetuximab–FOLFIRI group was 24.9 months (95% CI, 22.2 to 27.8), as compared with 21.0 months (95% CI, 19.2 
to 25.7) in the FOLFIRI group.
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ratio, 1.91; 95% CI, 1.24 to 2.93) (Fig. 2B). Among 
those with mutated-KRAS tumors, the response 
rate was 36.2% in the cetuximab–FOLFIRI group 
and 40.2% in the FOLFIRI group (odds ratio, 0.80; 
95% CI, 0.44 to 1.45).
Adverse Events
The overall incidence of grade 3 or 4 adverse events 
was 79.3% in the cetuximab–FOLFIRI group and 
61.0% in the FOLFIRI group (P<0.001) (Table 3); 
the incidence of any such events, excluding skin 
reactions, was 74.0% in the cetuximab–FOLFIRI 
group. The administration of cetuximab plus 
FOLFIRI, as compared with FOLFIRI alone, was 
associated with significantly more skin reactions 
(all) (19.7% vs. 0.2%, P<0.001) and acne-like rash 
(16.2% vs. 0.0%, P<0.001). None of the skin reac-
tions or acne-like rashes reported were grade 4. 
Median progression-free survival times among pa-
tients in the cetuximab–FOLFIRI group were found 
to increase with an increasing grade of rash. With 
cetuximab plus FOLFIRI, there was a higher inci-
dence of grade 3 or 4 diarrhea (15.7%, vs. 10.5% 
with FOLFIRI alone; P = 0.008) and infusion-relat-
ed reactions (2.5% vs. 0.0%, P<0.001), but these 
effects were able to be managed with protocol-
defined treatment modifications. The incidence of 
treatment-related serious adverse events was 26.0% 
with cetuximab plus FOLFIRI and 19.3% with 
FOLFIRI alone. There were no cetuximab-related 
deaths.
Discussion
We found that the initial treatment of metastatic 
colorectal cancer with a combination of cetuximab 
plus FOLFIRI, as compared with FOLFIRI alone, 
reduced the risk of disease progression by 15% 
(hazard ratio, 0.85; P = 0.048). The addition of 
cetuximab to FOLFIRI also increased the response 
rate by nearly 10%. There was no significant dif-
ference between the treatment groups in overall 
survival, however. Treatment added after the con-
clusion of a study can confound the analysis of 
overall survival,26,27 and in this study, approximate-
ly two thirds of patients in each group received 
subsequent chemotherapy after completion of the 
study, and 25.4% of patients in the FOLFIRI group 
and 6.2% in the cetuximab–FOLFIRI group re-
ceived EGFR antibody therapy after the study. Add-
ing cetuximab to FOLFIRI increased the rate of re-
section of metastases, but whether this increase 
Table 2. Efficacy in the Primary Analysis Population, According to Treatment Group.*
Variable
Cetuximab plus FOLFIRI 
(N = 599)
FOLFIRI Alone 
(N = 599)
Hazard Ratio or Odds 
Ratio (95% CI)† P Value‡
Progression-free survival
Progression event — no. (%) 298 (49.7) 322 (53.8) 0.85 (0.72–0.99) 0.048
Months of progression-free survival — 
median (95% CI)
8.9 (8.0–9.5) 8.0 (7.6–9.0)
Overall survival
Deaths — no. (%) 412 (68.8) 416 (69.4) 0.93 (0.81–1.07) 0.31
Months of overall survival — median 
(95% CI)
19.9 (18.5–21.3) 18.6 (16.6–19.8)
Response — no. (%)
Complete response 3 (0.5) 2 (0.3)
Partial response 278 (46.4) 230 (38.4)
Stable disease 224 (37.4) 280 (46.7)
Overall response rate
No. (%) 281 (46.9) 232 (38.7) 1.40 (1.12–1.77) 0.004
95% CI 42.9–51.0 34.8–42.8
* FOLFIRI denotes irinotecan, fluorouracil, and leucovorin.
† The ratios listed are hazard ratios, except for the overall response rate, for which the odds ratio is shown.
‡ P values were calculated with the use of the stratified log-rank test or, in the case of the overall response rate, the stratified Cochran–
Mantel–Haenszel test.
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improves the potential for cure or long-term sur-
vival is unknown.
Tumor tissue for the analysis of KRAS muta-
tion status was available from approximately half 
the patients. The incidence of KRAS mutations 
(36%) was in keeping with previous reports.28,29 
There was an interaction between treatment group 
and KRAS status for the response to cetuximab–
FOLFIRI (P = 0.03) but not for progression-free 
survival (P = 0.07) or overall survival (P = 0.44). The 
hazard ratio for progression-free survival among 
patients with wild-type–KRAS tumors in the ce-
t ux imab–FOLFIRI group, as compared with the 
FOLFIRI group, was 0.68 (95% CI, 0.50 to 0.94), 
which suggests that the cetuximab–FOLFIRI com-
bination reduces the risk of progression in such 
patients. The hazard ratio of 0.68 for progression-
free survival in this group is consistent with the 
hazard ratio of 0.57 reported in the randomized, 
phase 2 OPUS trial (Oxaliplatin and Cetuximab in 
First-Line Treatment of mCRC trial; ClinicalTrials.
gov number, NCT00125034), with cetuximab plus 
oxaliplatin, fluorouracil, and leucovorin (FOLFOX-4) 
among patients with wild-type–KRAS disease.30 It 
is also within the range of the hazard ratios for 
progression-free survival of 0.54 and 0.83 reported 
in association with combinations of two cytotoxic 
drugs plus bevacizumab.31,32 The predictive power 
of the KRAS mutation status of tumors with regard 
to their responsiveness to cetuximab has been 
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Figure 2. Hazard Ratios for Progression-free and Overall Survival and Odds Ratios with Tumor Response, According to the Mutation  
Status of KRAS in the Tumor.
For the primary analysis population, the hazard ratio for progression-free survival with cetuximab plus FOLFIRI as compared with FOLFIRI 
alone was significant (P = 0.048) (Panel A), as was the odds ratio for tumor response with cetuximab plus FOLFIRI (P = 0.004) (Panel B). 
The interaction between treatment group and KRAS mutation status was not significant for progression-free survival (P = 0.07) or overall 
survival (P = 0.44) (Panel A) but was significant for response (P = 0.03) (Panel B). In both panels, the sizes of the circles are proportional 
to the numbers of patients. 
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shown previously in studies of cetuximab, alone 
or in combination with irinotecan, administered 
to patients with metastatic colorectal cancer that 
had progressed after previous treatment.13-15,33,34 
A similar effect has also been reported in a study 
of previously treated patients receiving panitum-
umab in combination with the best supportive 
care.18,19
The safety profile of the cetuximab–FOLFIRI 
treatment was in line with that expected. The inci-
dence rates of grade 3 or 4 diarrhea, skin reac-
tions, and infusion-related reactions were signifi-
cantly higher with cetuximab plus FOLFIRI than 
with FOLFIRI alone, and the overall incidence of 
grade 3 or 4 adverse events was higher with cetux-
imab (79.3%, vs. 61.0%; P<0.001). However, these 
adverse events were generally manageable.
This trial provides confirmation that, as 
compared with FOLFIRI alone, cetuximab plus 
FOLFIRI reduces the risk of progression of meta-
static colorectal cancer when used as the first-line 
treatment and that this benefit is seen mainly in 
patients with wild-type–KRAS tumors.
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Table 3. Most Common Grade 3 or 4 Adverse Events and Special Adverse Event Categories in the Safety Population, 
According to Treatment Group.*
MedDRA Preferred Term†
Cetuximab plus 
FOLFIRI (N = 600)
FOLFIRI Alone 
(N = 602) P Value
no. (%)
Any 476 (79.3) 367 (61.0) <0.001
Neutropenia‡ 169 (28.2) 148 (24.6) 0.16
Leukopenia 43 (7.2) 31 (5.1) 0.15
Diarrhea 94 (15.7) 63 (10.5) 0.008
Fatigue 32 (5.3) 28 (4.7) 0.59
Rash 49 (8.2) 0 <0.001
Dermatitis acneiform 32 (5.3) 0 <0.001
Vomiting 28 (4.7) 30 (5.0) 0.80
Special adverse events
Skin reactions
All 118 (19.7) 1 (0.2) <0.001
Acne-like rash 97 (16.2) 0 <0.001
Infusion-related reaction 15 (2.5) 0 <0.001
* We used retrospective chi-square tests to compare the rates of adverse events between the two treatment groups; the 
results were not corrected for multiple testing. Under the assumption of no significant difference between the two 
groups, 11 independent tests and a 0.05 significance level results in a chance of more than 43% of obtaining at least 
one false positive finding. FOLFIRI denotes irinotecan, fluorouracil, and leucovorin.
† Among the Medical Dictionary for Regulatory Activities (MedDRA, version 10.0) preferred terms, no grade 4 reactions 
were reported for dermatitis acneiform, acne-like rash, or all skin reactions.
‡ Grade 3 or 4 febrile neutropenia was reported in 18 of the 600 patients (3.0%) receiving cetuximab plus FOLFIRI and in 
13 of the 602 patients (2.2%) receiving FOLFIRI alone.
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